Malaria morbidity in high and seasonal malaria transmission area of Burkina Faso.

Malaria morbidity in high and seasonal malaria transmission area of Burkina Faso.

Malariometric parameters are often primary endpoints of efficacy trials of malaria vaccine candidates. This study aims to describe the epidemiology of malaria prior to the conduct of a series of drug and vaccine trials in a rural area of Burkina Faso.Malaria incidence was prospectively evaluated ove...

Full description

Bibliographic Details
Main Authors:	Alphonse Ouédraogo, Alfred B Tiono, Amidou Diarra, Souleymane Sanon, Jean Baptiste Yaro, Esperance Ouedraogo, Edith C Bougouma, Issiaka Soulama, Adama Gansané, Amathe Ouedraogo, Amadou T Konate, Issa Nebie, Nora L Watson, Megan Sanza, Tina J T Dube, Sodiomon Bienvenu Sirima
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3540059?pdf=render

Similar Items

Seasonal performance of a malaria rapid diagnosis test at community health clinics in a malaria-hyperendemic region of Burkina Faso
by: Diarra Amidou, et al.
Published: (2012-05-01)

Haemoglobin variants and <it>Plasmodium falciparum</it> malaria in children under five years of age living in a high and seasonal malaria transmission area of Burkina Faso
by: Bougouma Edith C, et al.
Published: (2012-05-01)

Variation in haematological parameters in children less than five years of age with asymptomatic Plasmodium infection: implication for malaria field studies
by: Adama Gansane, et al.
Published: (2013-08-01)

Antibodies to malaria vaccine candidates are associated with chloroquine or sulphadoxine/pyrimethamine treatment efficacy in children in an endemic area of Burkina Faso
by: Diarra Amidou, et al.
Published: (2012-03-01)

Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial.
by: Amadou T Konaté, et al.
Published: (2011-02-01)

Hospital-based surveillance of severe paediatric malaria in two malaria transmission ecological zones of Burkina Faso
by: Alfred B. Tiono, et al.
Published: (2023-01-01)

Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.
by: Sodiomon B Sirima, et al.
Published: (2009-10-01)

Morbidity from malaria in children in the year after they had received intermittent preventive treatment of malaria: a randomised trial.
by: Amadou T Konaté, et al.
Published: (2011-01-01)

Correction: Safety and Immunogenicity of the Malaria Vaccine Candidate MSP3 Long Synthetic Peptide in 12–24 Months-Old Burkinabe Children.
by: Sodiomon B. Sirima, et al.
Published: (2010-01-01)

A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age.
by: Alphonse Ouédraogo, et al.
Published: (2013-01-01)

Malariometric Indices in the Context of Seasonal Malaria Chemoprevention in Children Aged 1.5 to 12 Years during the Period of High Malaria Transmission in the Suburban Area of Banfora, Burkina Faso
by: San M. Ouattara, et al.
Published: (2023-09-01)

Plasmodium falciparum malaria in children aged 0-2 years: the role of foetal haemoglobin and maternal antibodies to two asexual malaria vaccine candidates (MSP3 and GLURP).
by: David Tiga Kangoye, et al.
Published: (2014-01-01)

Antibody responses to P. falciparum blood stage antigens and incidence of clinical malaria in children living in endemic area in Burkina Faso
by: Mariama K. Cherif, et al.
Published: (2017-09-01)

Malaria incidence in children in South-West Burkina Faso: comparison of active and passive case detection methods.
by: Alfred B Tiono, et al.
Published: (2014-01-01)

Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children
by: Edith Christiane Bougouma, et al.
Published: (2022-08-01)

Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso
by: Richard Morter, et al.
Published: (2022-12-01)

Persistence of Anti-SE36 Antibodies Induced by the Malaria Vaccine Candidate BK-SE36/CpG in 5–10-Year-Old Burkinabe Children Naturally Exposed to Malaria
by: Issa Nebie, et al.
Published: (2024-02-01)

Risk factors for Plasmodium falciparum infection in pregnant women in Burkina Faso: a community-based cross-sectional survey
by: Jean Baptiste Yaro, et al.
Published: (2021-09-01)

Risk of Plasmodium falciparum infection in south-west Burkina Faso: potential impact of expanding eligibility for seasonal malaria chemoprevention
by: Jean Baptiste Yaro, et al.
Published: (2022-01-01)

Haematological parameters, natural regulatory CD4 + CD25 + FOXP3+ T cells and γδ T cells among two sympatric ethnic groups having different susceptibility to malaria in Burkina Faso
by: Sanou Guillaume S, et al.
Published: (2012-01-01)

Plasmodium falciparum malaria in children aged 0-2 years: the role of foetal haemoglobin and maternal antibodies to two asexual malaria vaccine candidates (MSP3 and GLURP)
by: Kangoye, D, et al.
Published: (2014)

The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated <it>Plasmodium falciparum</it>
by: Kiechel Jean, et al.
Published: (2009-03-01)

<i>In vitro</i> antiplasmodial and cytotoxic properties of some medicinal plants from western Burkina Faso
by: Souleymane Sanon, et al.
Published: (2013-03-01)

Understanding and maximising the community impact of seasonal malaria chemoprevention in Burkina Faso (INDIE-SMC): study protocol for a cluster randomised evaluation trial
by: John Bradley, et al.
Published: (2024-03-01)

Contribution of the Rapid LAMP-Based Diagnostic Test (RLDT) to the Evaluation of Enterotoxigenic <i>Escherichia coli</i> (ETEC) and <i>Shigella</i> in Childhood Diarrhea in the Peri-Urban Area of Ouagadougou, Burkina Faso
by: Alimatou Héma, et al.
Published: (2023-11-01)

Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial
by: Alphonse Ouédraogo, et al.
Published: (2023-10-01)

Safety and immunogenicity of co-administration of meningococcal type A and measles–rubella vaccines with typhoid conjugate vaccine in children aged 15–23 months in Burkina Faso
by: Sodiomon B. Sirima, et al.
Published: (2021-01-01)

Plasmodium falciparum infection coinciding with the malaria vaccine candidate BK-SE36 administration interferes with the immune responses in Burkinabe children
by: Alfred B. Tiono, et al.
Published: (2023-03-01)

Different approaches for delivery of Intermittent Preventive Treatment (IPT) to pregnant women in Burkina Faso
by: Traoré Abdoulaye, et al.
Published: (2010-10-01)

Stakeholder perceptions on the deployment of multiple first-line therapies for uncomplicated malaria: a qualitative study in the health district of Kaya, Burkina Faso
by: Denise Hien, et al.
Published: (2022-06-01)

Safety and Immunogenicity of the malaria vaccine candidate R21 adjuvanted with matrix-m1 in West African adult volunteers, Burkina Faso
by: Tiono, AB, et al.
Published: (2017)

Attitudes, practices, and determinants of community care-seeking behaviours for fever/malaria episodes in the context of the implementation of multiple first-line therapies for uncomplicated malaria in the health district of Kaya, Burkina Faso
by: Jean Moise Tanga Kaboré, et al.
Published: (2022-05-01)

Risk factors associated with house entry of malaria vectors in an area of Burkina Faso with high, persistent malaria transmission and high insecticide resistance
by: Jean Baptiste Yaro, et al.
Published: (2021-10-01)

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children.
by: Alfred B Tiono, et al.
Published: (2018-01-01)

Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors.
by: Nébié, I, et al.
Published: (2014)

Correction for nebie et Al., assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors.
by: Nébié, I, et al.
Published: (2014)

Population pharmacokinetics of artesunate and amodiaquine in African children
by: Ouedraogo Alphonse, et al.
Published: (2009-08-01)

Seasonal Malaria Chemoprevention Implementation: Effect on Malaria Incidence and Immunity in a Context of Expansion of P. falciparum Resistant Genotypes with Potential Reduction of the Effectiveness in Sub-Saharan Africa
by: Nikiema S, et al.
Published: (2022-08-01)

Feasibility and Acceptability of a Strategy Deploying Multiple First-Line Artemisinin-Based Combination Therapies for Uncomplicated Malaria in the Health District of Kaya, Burkina Faso
by: Jean Moïse Tanga Kaboré, et al.
Published: (2023-03-01)

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children
by: Tiono, AB, et al.
Published: (2018)